Market Overview

Novocure Announces Addition to Its Board of Directors


Jeryl Hilleman, Chief Financial Officer of Intersect ENT,
elected to board of directors

Novocure (NASDAQ:NVCR) has announced an addition to its board of
directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was
elected to Novocure's board in July 2018.

"We are extremely pleased to welcome Jeri to our board of directors,"
said Bill Doyle, Novocure's Executive Chairman. "Her significant
biopharmaceutical and medical device experience as well as her finance,
strategy and leadership skills will be invaluable as we grow our
glioblastoma (GBM) business and advance our proprietary cancer therapy
to commercialize indications beyond GBM."

Ms. Hilleman is Chief Financial Officer of Intersect ENT (NASDAQ:XENT),
a medical device company with commercial products for the treatment of
chronic sinusitis. Prior to joining Intersect ENT, she was Chief
Financial Officer of Amyris Inc., a multi-national, renewable products
company based in California and Brazil, from January 2008 to June 2012.
Ms. Hilleman was a member of the board of directors and chair of the
audit committee at Xenoport Inc., a commercial biopharmaceutical
company, from January 2004 to July 2018. She also served as Chief
Financial Officer of Symyx Technologies, a research services, software
and instrumentation company, Ocera, a biopharmaceutical company, and
Cytel, an immunotherapy company. She is also a director of Minerva
Neurosciences (NASDAQ:NERV). Jeri holds an A.B. from Brown
University and an MBA from the Wharton Graduate School of Business. She
is a member of the 1999 class of Henry Crown Fellows and the Aspen
Global Leadership Network at the Aspen Institute.

About Novocure

Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure's commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit
or follow us at

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure's current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage, collections
from third-party payers and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning. Novocure's performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2018, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.

View Comments and Join the Discussion!